Saturday November 23, 2019

UN Report: 30% Increase in Drug Usage, 35 Million Suffering from Disorders

The death toll also increased, with 5,85,000 people dying in 2017 from drug use

0
//
health, facebook, depression
Social media users are 63 per cent less likely to experience serious psychological distress from one year to the next, including major depression or serious anxiety. Pixabay

The United Nation’s latest report on drug use revealed a 30 per cent increase on 2009 with regards to the consumption of narcotics with some 35 million people worldwide suffering from drug disorders, thanks to in-depth surveys conducted in India and Nigeria.

The UN has raised the alarm on the need for further international cooperation to deal with the health and criminal impact of substance misuse, the Efe news reported.”

“The findings of this’year’s World Drug Report fill in and further complicate the global picture of drug challenges, underscoring the need for broader international cooperation to advance balanced and integrated health and criminal justice responses to supply and de”and,” Yury Fedotov, Executive Director of the UN’s Office on Drugs and Crime (UNODC), said.

“With improved research and more precise data from India and Nigeria, both amongst the 10 most populous countries in the world – we see that there are any more opioid users and people with use disorders than previously estimated,” Fedotov added.

drug
The studies have contributed to more accurate figures of drug use globally. Pixabay

The surveys in India in 2018 and Nigeria in 2017 have offered great insights into drug consumption due to being such vast demographics for their region. India accounts for 30 per cent of the population in Asia alone.

The Indian survey was based on interviews with 5,00,000 people across the nation. The studies have contributed to more accurate figures of drug use globally. The report estimated that of the 271 million people that used any drug, 35 million (nearly 13 per cent) suffer from a disorder.

Previous records fell 4.5 million people short in their estimates and it was the surveys conducted in both India and Nigeria that triggered the adjustment. The death toll also increased, with 5,85,000 people dying in 2017 from drug use.

Cannabis consumption, the most widely used drug globally with approximately 188 million users in 2016, has increased in Asia and North and South America, whilst a spike in use of opioids was registered.

Opioids are the drugs that present the largest cause for concern due to the severe impact on the health of users. Also of concern is the non-medical use of painkiller Tramadol produced in South Asia and trafficked primarily to Africa and the Middle East.

drug
The report estimated that of the 271 million people that used any drug, 35 million (nearly 13 per cent) suffer from a drug use disorder. VOA

Amongst the negative consequences of drug use, mental health disorders, HIV infection, hepatitis C and overdose are the main concerns, many of which can lead to premature death.

Injecting drugs, mainly opioids, is deemed the most dangerous way of consuming narcotics due to the proliferation of diseases through the sharing of needles. The rate of 15-64 year olds who inject drugs is four times higher in eastern and southeastern Europe and in central Asia.

ALSO READ: Poor Sleep Quality Associated with Reduced Memory in Senior Citizens

According to the report, 50 per cent of those live with hepatitis C. Mortality rates overwhelmingly affect men who account for 72 per cent of those who die as a result of drug use. Sixty-eight per cent of overdose deaths in 2017 were due to opioids.

Most of the world’s opioids are produced in Afghanistan (263,000 hectares of poppy seed production) with Myanmar (37,300 hectares) coming in as the second largest producer amid a decline in consumption in Asia as the demand for synthetic drugs increased, particularly methamphetamine. (IANS)

Next Story

China Okays Sale of First Home-Grown Drug for Treatment of Mild to Moderate Alzheimer’s Disease

A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020

0
China, Home, Drug
Oligomannate will provide a new treatment option to fight Alzheimer's disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday. Pixabay

China has approved the first home-grown drug for the treatment of “mild to moderate Alzheimer’s disease (AD) and improving cognitive function”, according to its developers.

The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences.

Oligomannate will provide a new treatment option to fight Alzheimer’s disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday.

A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020 to support global regulatory filing of Oligomannate.

China, Home, Drug
The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences. Pixabay

An effective treatment for Alzheimer’s that affects about 48 million people in the world could easily become a big hit globally.

China’s National Medical Products Administration granted Oligomannate fast-track review in November 2018.

Over 800 patients with the diagnosis of mild to moderate Alzhemer’s disease completed the Phase 3 clinical trial conducted in 34 tier-1 hospitals across China.

Results of the 36-week-long study showed that Oligomannate can improve cognitive function in mild-to-moderate Alzheimer’s disease patients as early as week 4 and the benefit was sustained at each follow-up assessment visit.

Also Read- Bengal Focuses on Alternatives after Banning Stubble Burning

Alzheimer’s disease is a progressive brain disorder that impairs memory, affecting the ability of patients to carry out simple tasks. (IANS)